/

KYMR

Kymera Therapeutics, Inc.Open

111.10−0.98 −0.87%USD

NasdaqGM · as of Oct 13, 10:18 ET · 15m delay

Open

110.83

Prev close

112.08

Day range

110.03112.00

52-week range

55.26130.05

Volume

98.45K0.14×

Mkt cap

9.14B

P/E ttm

—

Fwd P/E

-21.80

EPS ttm

-3.25

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−14.57%

Price Chart

Yahoo Finance · delayed

KYMROct 13, 2026O 110.83H 112.00L 110.03C 111.10−0.98 (−0.87%)Vol 98.45K

SMA 50115.00
SMA 20093.97

1Y change +94.20% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

KYMR Kymera Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +4.83%
1 month: −3.36%
3 months: −0.87%
6 months: +23.63%
Year to date: +42.78%
1 year: +85.51%

Valuation & ownership

Market cap: 9.14B
Enterprise value: 8.71B
P/E (ttm): —
Forward P/E: -21.80
PEG ratio: —
Price / book: 6.09
Price / sales (ttm): 87.04
EV / EBITDA: -25.62
EPS (ttm): -3.25
EPS (forward): -5.10
Beta (5y monthly): 1.98
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 82.26M
Float: 66.04M
Short % of float: 15.33%
Short ratio (days): 13.18
Held by insiders: 2.12%
Held by institutions: 119.39%
Avg volume (3m): 711.38K
50-day average: 114.79
200-day average: 93.83
52-week change: +85.51%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 46.9
vs 50-day SMA: −3.39%
vs 200-day SMA: +18.23%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 4.74%
Realised vol (20d, ann.): 38.4%
From 52-week high: −14.57%
From 52-week low: +101.05%

ANR

Analyst Consensus

23 analysts

Consensus

Strong buy

1.38 on a 1 (strong buy) – 5 (sell) scale

Mean target

139.35

+25.43% implied

Low 111.00Median 139.00High 180.00

Recommendation trend

Now22 / 2 / 0
1m ago

DES

About Kymera Therapeutics, Inc.

Yahoo Finance profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 273
Headquarters: Watertown, MA, United States
Website: kymeratx.com
Officers: Dr. Nello Mainolfi M.D., Ph.D. Co-Founder, President, CEO & Director
Mr. Bruce N. Jacobs CFA Chief Financial Officer

SEAS

Seasonality · KYMR

2020–2026 · monthly returns

Strongest month Nov +18.09%Weakest month May −14.71%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-6.6	25.7	-8.8	-2.7	0.4	40.8	-9.8	14.9	-5.9	-0.6			+42.8%
2025	-1.6	-20.8	-12.7	25.2	-13.5	47.2	0.3	-5.8	37.4	9.3	9.8	14.6	+93.4%
2024	28.8	30.3	-5.9	-16.4	-4.5	-7.0	54.8	4.7	-2.1	-2.5	1.5	-14.1	+58.0%
2023	49.8	-16.1	-5.6	6.4	-6.7	-21.9	-4.8	-12.8	-27.1	-16.0	77.9	22.6	+2.0%
2022	-33.8	-5.3	6.4	-25.9	-54.5	38.0	11.9	28.3	-23.0	39.4	-4.5	-13.9	−60.7%
2021	-0.1	-22.6	-19.0	17.2	5.6	0.9	24.1	3.3	-5.5	0.2	-5.7	14.4	+2.4%
2020									1.3	11.4	29.6	32.9	+94.4%

INSD

Insider Activity · KYMR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

335.4K shares

Sells, 6 months

1.94M shares

Net shares

−1.61M

Net change in insider shares

−47.70%

Date	Insider	Transaction	Shares	Value
Sep 30, 2026	Mainolfi NelloChief Executive Officer	Sale at price 111.44 - 116.12 per share.	30K	$3.41M
Sep 30, 2026	Mainolfi NelloChief Executive Officer	Conversion of Exercise of derivative security at price 2.08 per share.	30K	$62.40K
Sep 3, 2026	Adams Brian ROfficer	Sale at price 115.55 - 117.57 per share.	6.4K	$744.30K
Jul 26, 2026	Rooney TerenceOfficer	Stock Award(Grant) at price 0.00 per share.	38K	—
Jul 6, 2026	Mainolfi NelloChief Executive Officer	Sale at price 119.00 per share.	50K	$5.95M
Jul 6, 2026	Mainolfi NelloChief Executive Officer	Conversion of Exercise of derivative security at price 2.08 per share.	50K	$104.00K
Jun 30, 2026	Mainolfi NelloChief Executive Officer	Sale at price 112.80 - 116.56 per share.	80K	$9.22M
Jun 30, 2026	Mainolfi NelloChief Executive Officer	Conversion of Exercise of derivative security at price 2.08 per share.	80K	$166.40K
Jun 30, 2026	Goodman NoahOfficer	Sale at price 114.29 per share.	3.4K	$387.33K
Jun 29, 2026	Jacobs Bruce N.Chief Financial Officer	Sale at price 110.54 - 117.70 per share.	77.1K	$8.86M
Jun 29, 2026	Jacobs Bruce N.Chief Financial Officer	Conversion of Exercise of derivative security at price 5.33 per share.	61.4K	$327.14K
Jun 25, 2026	Bvf Partners L.P.Affiliated Person	Sale at price 106.50 per share.	1.63M	$173.67M
Jun 24, 2026	Goodman NoahOfficer	Sale at price 109.00 - 119.00 per share.	5K	$570.00K
Jun 24, 2026	Goodman NoahOfficer	Conversion of Exercise of derivative security at price 21.05 per share.	5K	$105.25K
Jun 21, 2026	Goodman NoahOfficer	Sale at price 99.00 per share.	2.5K	$247.50K
Jun 21, 2026	Goodman NoahOfficer	Conversion of Exercise of derivative security at price 21.05 per share.	2.5K	$52.63K
Jun 1, 2026	Jacobs Bruce N.Chief Financial Officer	Conversion of Exercise of derivative security at price 2.08 per share.	12.7K	$26.32K
May 26, 2026	Chadwick Jeremy GChief Operating Officer	Sale at price 78.36 - 82.08 per share.	17.2K	$1.37M
May 18, 2026	Esposito PamelaDirector	Conversion of Exercise of derivative security at price 31.20 per share.	1K	$31.20K
May 17, 2026	Jacobs Bruce N.Chief Financial Officer	Conversion of Exercise of derivative security at price 2.08 per share.	15K	$31.20K

KYMR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

KYMR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Kymera Therapeutics, Inc.

Seasonality · KYMR

Insider Activity · KYMR

Congress Trades · KYMR

Investors Holding KYMR

Investors Holding KYMR

Congress Trades · KYMR

Insider Activity · KYMR

Seasonality · KYMR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Kymera Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News